{'output': [['ICON plc', 'ORG', 'Has', 'Drug Development Solutions', 'CONCEPT'], ['ICON plc', 'ORG', 'Operate_In', 'Pharmaceutical Industry', 'SECTOR'], ['ICON plc', 'ORG', 'Operate_In', 'Biotechnology Industry', 'SECTOR'], ['ICON plc', 'ORG', 'Operate_In', 'Medical Device Industry', 'SECTOR'], ['ICON plc', 'ORG', 'Has', 'NASDAQ: ICLR', 'FIN_INSTRUMENT'], ['ICON plc', 'ORG', 'Located_In', 'Dublin', 'GPE'], ['ICON plc', 'ORG', 'Operate_In', '38 Countries', 'GPE'], ['ICON plc', 'ORG', 'Has', 'Approximately 13,100 Employees', 'CONCEPT'], ['ICON plc', 'ORG', 'Announce', 'Financial Guidance for Year Ended December 31, 2018', 'CONCEPT'], ['ICON plc', 'ORG', 'Expect', 'Revenue Growth of 7 - 10%', 'ECON_INDICATOR'], ['ICON plc', 'ORG', 'Expect', 'Earnings Per Share Growth of 10 - 13%', 'ECON_INDICATOR'], ['ICON plc', 'ORG', 'Reduce', 'Top Customer Concentration to 12 - 14%', 'ECON_INDICATOR'], ['ICON plc', 'ORG', 'Expect', 'Circa $360 Million of Free Cash Flow', 'ECON_INDICATOR'], ['ICON plc', 'ORG', 'Expect', 'Capital Expenditures of Circa $50 Million', 'ECON_INDICATOR'], ['ICON plc', 'ORG', 'Repurchase', 'Shares Worth $25 Million in Q4 2017', 'CONCEPT'], ['ICON plc', 'ORG', 'Remaining Authorisation', 'Up to $157 Million for Share Repurchases', 'CONCEPT'], ['ICON plc', 'ORG', 'Confirm', 'Current Guidance for 2017 Revenue and Earnings', 'CONCEPT'], ['ICON plc', 'ORG', 'Present', 'At JP Morgan Healthcare Conference on January 9th, 2018', 'EVENT'], ['ICON plc', 'ORG', 'Make', 'Forward-Looking Statements', 'CONCEPT']]}